3 chemin du PrE-Fleuri
Plan-les-Ouates 1228
Switzerland
41 22 552 48 00
https://www.geneuro.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 19
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Jesus Martin-Garcia | Chairman & CEO | 652,59k | S.O. | 1962 |
Mr. Miguel Payró | Chief Financial Officer | S.O. | S.O. | 1965 |
Dr. Hervé Perron | Chief Scientific Officer | S.O. | S.O. | 1959 |
Dr. Alois B. Lang Ph.D. | Chief Development Officer | S.O. | S.O. | 1952 |
Dr. Anke Post M.D., Ph.D. | Chief Medical Officer | S.O. | S.O. | S.O. |
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
L’ISS Governance QualityScore de GeNeuro SA en date du 1 avril 2024 est 10. Les scores principaux sont Audit : 9; Société : 10; Droits des actionnaires : 1; Compensation : 10.